163 related articles for article (PubMed ID: 16190565)
21. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
[TBL] [Abstract][Full Text] [Related]
22. Management of hepatitis C.
Smith C
Minn Med; 2003 Jun; 86(6):53-6. PubMed ID: 12834215
[TBL] [Abstract][Full Text] [Related]
23. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
24. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
25. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
26. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
27. HCV infection and hemodialysis.
Pol S; Vallet-Pichard A; Fontaine H; Lebray P
Semin Nephrol; 2002 Jul; 22(4):331-9. PubMed ID: 12118398
[TBL] [Abstract][Full Text] [Related]
28. Treatment of a common problem in hemodialysis patients: is the juice worth the squeeze?
Al-Saran K; Sabry A; Shaheen N; Yehia A
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):876-82. PubMed ID: 19736496
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection].
Peters L; Lindhardt BØ
Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721
[TBL] [Abstract][Full Text] [Related]
30. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
MMW Fortschr Med; 2003 Jun; 145(26):52-3. PubMed ID: 12916339
[No Abstract] [Full Text] [Related]
31. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus infection in dialysis patients.
Sułowicz W; Radziszewski A; Chowaniec E
Hemodial Int; 2007 Jul; 11(3):286-95. PubMed ID: 17576291
[TBL] [Abstract][Full Text] [Related]
33. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
34. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
35. Evolving strategies to attack hepatitis C.
Norton M
GMHC Treat Issues; 1998 Dec; 12(12):1-5. PubMed ID: 11366019
[TBL] [Abstract][Full Text] [Related]
36. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
37. Management of hepatitis C virus coinfection in HIV-infected persons.
O'Leary JG; Chung RT
AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
[TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
[TBL] [Abstract][Full Text] [Related]
39. Results of hepatitis C virus treatment in patients on hemodialysis: data from published meta-analyses in 2008.
Casanovas Taltavull T; Baliellas Comellas C; Cruzado Garrit JM
Transplant Proc; 2009; 41(6):2082-4. PubMed ID: 19715837
[TBL] [Abstract][Full Text] [Related]
40. Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?
Althaf MM; Abdelsalam MS; Rashwan M; Nadri Q
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24907214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
